Literature DB >> 23464402

Association between mismatch repair gene MSH3 codons 1036 and 222 polymorphisms and sporadic prostate cancer in the Iranian population.

Fariba Jafary1, Mansoor Salehi, Maryam Sedghi, Nayereh Nouri, Farzaneh Jafary, Farzaneh Sadeghi, Shima Motamedi, Maede Talebi.   

Abstract

The mismatch repair system (MMR) is a post-replicative DNA repair mechanism whose defects can lead to cancer. The MSH3 protein is an essential component of the system. We postulated that MSH3 gene polymorphisms might therefore be associated with prostate cancer (PC). We studied MSH3 codon 222 and MSH3 codon 1036 polymorphisms in a group of Iranian sporadic PC patients. A total of 60 controls and 18 patients were assessed using the polymerase chain reaction and single strand conformational polymorphism. For comparing the genotype frequencies of patients and controls the chi-square test was applied. The obtained result indicated that there was significantly association between G/A genotype of MSH3 codon 222 and G/G genotype of MSH3 codon 1036 with an increased PC risk (P=0.012 and P=0.02 respectively). Our results demonstrated that MSH3 codon 222 and MSH3 codon 1036 polymorphisms may be risk factors for sporadic prostate cancer in the Iranian population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23464402     DOI: 10.7314/apjcp.2012.13.12.6055

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis.

Authors:  Ronja Adam; Isabel Spier; Bixiao Zhao; Michael Kloth; Jonathan Marquez; Inga Hinrichsen; Jutta Kirfel; Aylar Tafazzoli; Sukanya Horpaopan; Siegfried Uhlhaas; Dietlinde Stienen; Nicolaus Friedrichs; Janine Altmüller; Andreas Laner; Stefanie Holzapfel; Sophia Peters; Katrin Kayser; Holger Thiele; Elke Holinski-Feder; Giancarlo Marra; Glen Kristiansen; Markus M Nöthen; Reinhard Büttner; Gabriela Möslein; Regina C Betz; Angela Brieger; Richard P Lifton; Stefan Aretz
Journal:  Am J Hum Genet       Date:  2016-07-28       Impact factor: 11.025

2.  MSH3 rs26279 polymorphism increases cancer risk: a meta-analysis.

Authors:  Hui-Kai Miao; Li-Ping Chen; Dong-Ping Cai; Wei-Ju Kong; Li Xiao; Jie Lin
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.

Authors:  Mev Dominguez-Valentin; Patrick Joost; Christina Therkildsen; Mats Jonsson; Eva Rambech; Mef Nilbert
Journal:  BMC Urol       Date:  2016-03-24       Impact factor: 2.264

4.  Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer.

Authors:  Emmanuelle Nicolas; Sanjeevani Arora; Yan Zhou; Ilya G Serebriiskii; Mark D Andrake; Elizabeth D Handorf; Dale L Bodian; Joseph G Vockley; Roland L Dunbrack; Eric A Ross; Brian L Egleston; Michael J Hall; Erica A Golemis; Veda N Giri; Mary B Daly
Journal:  Oncotarget       Date:  2015-11-24

5.  Inactivation of MSH3 by promoter methylation correlates with primary tumor stage in nasopharyngeal carcinoma.

Authors:  Haifeng Ni; Bo Jiang; Zhen Zhou; Xiaoyang Yuan; Xiaolin Cao; Guangwu Huang; Yong Li
Journal:  Int J Mol Med       Date:  2017-06-27       Impact factor: 4.101

6.  Significance of rare variants in genes involved in the pathogenesis of Lynch syndrome.

Authors:  Raffaella Liccardo; Matilde Lambiase; Antonio Nolano; Marina De Rosa; Paola Izzo; Francesca Duraturo
Journal:  Int J Mol Med       Date:  2022-04-27       Impact factor: 5.314

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.